Sarcopenia in the setting of nonalcoholic fatty liver

Abstract

Nonalcoholic fatty liver is a worldwide common problem with more prevalence in non-Asian populations that is closely correlated with the muscle-related disorder sarcopenia. The incidence of both health issues has been observed to be strongly interlinked where presence of one exacerbates the other. Nonalcoholic fatty liver disease (NAFLD) pathophysiology increases the muscle loss, while the onset of NAFLD in sarcopenic patients aggravates the liver problems as compared to non-sarcopenic patients. Scarcity of research on the subject provides very little evidence about the cause and effect of disorders. No FDA approved drugs are available to date for NAFLD and sarcopenia. Research is underway to understand the complex biochemical pathways involved in the development of both disorders. This review is a small contribution toward understanding sarcopenia in the setting of NAFLD that provides insight on the common pathophysiological profile of sarcopenia and NAFLD and portrays a novel way of delving into the subject by introducing the concept of cortisol crosstalk with the muscle-liver axis. Sarcopenia and NAFLD are considered metabolism-related problems, and cortisol, being a glucocorticoid, plays an important role in metabolism of fats, carbohydrates, and proteins. Cushing’s syndrome, characterized by abnormally elevated concentrations of blood cortisol/enhanced intracellular activity, shares many pathologic conditions (such as insulin resistance, metabolic syndrome, abnormal levels of specific cytokines, and obesity) with NAFLD and sarcopenia. Hence, cortisol can be a potential biomarker in sarcopenia and NAFLD. As cortisol activity at cellular level is controlled by 11β-hydroxysteroid dehydrogenase type 1 and 2 (11β-HSD1/2) enzymes that convert inactive steroid precursor into active cortisol, these enzymes can be targeted for the study of sarcopenia and NAFLD. Combined studies on NAFLD and sarcopenia with respect to cortisol open a new avenue of research in the understanding of both disorders.

Keywords

Sarcopenia / NAFLD / cortisol / 11β-HSD1 / 11β-HSD2 / muscle-liver axis / insulin resistance

References

[1] Rosenberg IH.Summary comments.Am J Clin Nutr1989;50:1231-3

[2] Siparsky PN,Garrett WE Jr.Muscle changes in aging: understanding sarcopenia.Sports Health2014;6:36-40 PMCID:PMC3874224

[3] Cruz-Jentoft AJ,Bauer J.Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2)and the Extended Group for EWGSOP2Sarcopenia: revised European consensus on definition and diagnosis.Age Ageing2019;48:16-31 PMCID:PMC6322506

[4] Chakravarthy MV,Forsgren MF.Harnessing muscle-liver crosstalk to treat nonalcoholic steatohepatitis.Front Endocrinol (Lausanne)2020;11:592373 PMCID:PMC7786290

[5] Hong HC,Choi HY.Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study.Hepatology2014;59:1772-8

[6] Koo BK,Joo SK.Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.J Hepatol2017;66:123-31

[7] Cai C,Chen Y,Yu C.Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis.Hepatol Int2020;14:115-26 PMCID:PMC6994447

[8] Kim G,Lee YB.Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study.Hepatology2018;68:1755-68

[9] Mikolasevic I,Kanizaj TF,Domislovic V.Nonalcoholic fatty liver disease and sarcopenia: where do we stand?.Can J Gastroenterol Hepatol2020;2020:8859719 PMCID:PMC7652636

[10] Angulo P.Nonalcoholic fatty liver disease.N Engl J Med2002;346:1221-31

[11] Younossi Z,Arrese M.Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Hepatology2019;69:2672-82

[12] Su W,Jia X.Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease.Proc Natl Acad Sci U S A2014;111:11437-42 PMCID:PMC4128098

[13] Altajar S.Skeletal muscle dysfunction in the development and progression of nonalcoholic fatty liver disease.J Clin Transl Hepatol2020;8:414-23 PMCID:PMC7782111

[14] Severinsen MCK.Muscle-organ crosstalk: the emerging roles of myokines.Endocr Rev2020;41:594-609 PMCID:PMC7288608

[15] de Oliveira Dos Santos AR,Miola VFB.Adipokines, myokines, and hepatokines: crosstalk and metabolic repercussions.Int J Mol Sci2021;22:2639 PMCID:PMC7961600

[16] Pedersen BK.Muscles, exercise and obesity: skeletal muscle as a secretory organ.Nat Rev Endocrinol2012;8:457-65

[17] Keller K.Strength and muscle mass loss with aging process. Age and strength loss.Muscles Ligaments Tendons J2014;3:346-50 PMCID:PMC3940510

[18] Beaudart C,Bruyère O.Sarcopenia in daily practice: assessment and management.BMC Geriatr2016;16:170 PMCID:PMC5052976

[19] Shafiee G,Soltani A,Larijani B.Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies.J Diabetes Metab Disord2017;16:21 PMCID:PMC5434551

[20] Papadopoulou SK,Potsaki P.Differences in the prevalence of sarcopenia in community-dwelling, nursing home and hospitalized individuals. A systematic review and meta-analysis.J Nutr Health Aging2020;24:83-90

[21] Aleixo GFP,Nyrop KA,Shachar SS.Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.Breast Cancer Res Treat2019;177:569-79

[22] Bone AE,Kon S.Sarcopenia and frailty in chronic respiratory disease.Chron Respir Dis2017;14:85-99 PMCID:PMC5720213

[23] Sui SX,Holloway-Kew KL,Pasco JA.Skeletal muscle health and cognitive function: a narrative review.Int J Mol Sci2020;22:255 PMCID:PMC7795998

[24] Petta S,Di Marco V.Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.Aliment Pharmacol Ther2017;45:510-8

[25] Wilkinson TJ,Yates T.Association of sarcopenia with mortality and end-stage renal disease in those with chronic kidney disease: a UK Biobank study.J Cachexia Sarcopenia Muscle2021;12:586-98 PMCID:PMC8200422

[26] Vogel F,Rubinstein G.Persisting muscle dysfunction in Cushing’s syndrome despite biochemical remission.J Clin Endocrinol Metab2020;105:e4490-8 PMCID:PMC7538105

[27] Fuggle N,Dennison E.Sarcopenia.Best Pract Res Clin Rheumatol2017;31:218-42 PMCID:PMC5768235

[28] Riuzzi F,Arcuri C.Cellular and molecular mechanisms of sarcopenia: the S100B perspective.J Cachexia Sarcopenia Muscle2018;9:1255-68 PMCID:PMC6351675

[29] Dalle S,Koppo K.The role of inflammation in age-related sarcopenia.Front Physiol2017;8:1045 PMCID:PMC5733049

[30] Alemán H,Ramirez FA,Payette H.Longitudinal evidence on the association between interleukin-6 and C-reactive protein with the loss of total appendicular skeletal muscle in free-living older men and women.Age Ageing2011;40:469-75

[31] Li CW,Shyh-Chang N.Circulating factors associated with sarcopenia during ageing and after intensive lifestyle intervention.J Cachexia Sarcopenia Muscle2019;10:586-600 PMCID:PMC6596393

[32] Sakellariou GK,Earl KE,McDonagh B.Redox homeostasis and age-related deficits in neuromuscular integrity and function.J Cachexia Sarcopenia Muscle2017;8:881-906 PMCID:PMC5700439

[33] Thoma A,Reade RL.Targeting reactive oxygen species (ROS) to combat the age-related loss of muscle mass and function.Biogerontology2020;21:475-84 PMCID:PMC7347670

[34] Boengler K,Mayr M,Rohrbach S.Mitochondria and ageing: role in heart, skeletal muscle and adipose tissue.J Cachexia Sarcopenia Muscle2017;8:349-69 PMCID:PMC5476857

[35] Dirks AJ.The role of apoptosis in age-related skeletal muscle atrophy.Sports Med2005;35:473-83

[36] Lo JH,Yiu T,Lee WY.Sarcopenia: current treatments and new regenerative therapeutic approaches.J Orthop Translat2020;23:38-52 PMCID:PMC7256062

[37] Hunter GR,Carter SJ,Fisher G.Sarcopenia and Its Implications for Metabolic Health.J Obes2019;2019:8031705 PMCID:PMC6431367

[38] Cleasby ME,Atherton PJ.Insulin resistance and sarcopenia: mechanistic links between common co-morbidities.J Endocrinol2016;229:R67-81

[39] Schoufour JD,Barazzoni R.The relevance of diet, physical activity, exercise, and persuasive technology in the prevention and treatment of sarcopenic obesity in older adults.Front Nutr2021;8:661449 PMCID:PMC8180560

[40] Guillet C.Insulin resistance: a contributing factor to age-related muscle mass loss?.Diabetes Metab2005;31:5S20-6

[41] Katsanos CS.Protein metabolism in human obesity: a shift in focus from whole-body to skeletal muscle.Obesity (Silver Spring)2011;19:469-75

[42] Borst SE.Interventions for sarcopenia and muscle weakness in older people.Age Ageing2004;33:548-55

[43] Christiansen AR,Hotaling JM.Selective androgen receptor modulators: the future of androgen therapy?.Transl Androl Urol2020;9:S135-48 PMCID:PMC7108998

[44] Neil D,Magee M.GSK2881078, a SARM, Produces dose-dependent increases in lean mass in healthy older men and women.J Clin Endocrinol Metab2018;103:3215-24

[45] Dalton JT,Bohl CE.The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.J Cachexia Sarcopenia Muscle2011;2:153-61 PMCID:PMC3177038

[46] Dobs AS,Croot CC.Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.Lancet Oncol2013;14:335-45 PMCID:PMC4898053

[47] Lambert CP.Should the FDA’s criteria for the clinical efficacy of cachexia drugs be changed?.J Cachexia Sarcopenia Muscle2021;12:531-2 PMCID:PMC8200429

[48] Elkina Y,Anker SD.The role of myostatin in muscle wasting: an overview.J Cachexia Sarcopenia Muscle2011;2:143-51 PMCID:PMC3177043

[49] Suh J.Myostatin inhibitors: panacea or predicament for musculoskeletal disorders?.J Bone Metab2020;27:151-65 PMCID:PMC7571243

[50] Consitt LA.The vicious cycle of myostatin signaling in sarcopenic obesity: myostatin role in skeletal muscle growth, insulin signaling and implications for clinical trials.J Frailty Aging2018;7:21-7 PMCID:PMC6909929

[51] Guo T,Chanturiya T,Gavrilova O.Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity.PLoS One2009;4:e4937 PMCID:PMC2654157

[52] Dong J,Dong Y,Mitch WE.Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues.Int J Obes (Lond)2016;40:434-42 PMCID:PMC4783239

[53] Zhu HJ,Wang XQ.Serum myostatin levels are elevated in overweight patients.TOOBESJ2014;6:31-7

[54] Milan G,Pilon C.Changes in muscle myostatin expression in obese subjects after weight loss.J Clin Endocrinol Metab2004;89:2724-7

[55] Pan H,Zhu HJ.Association of myostatin gene polymorphisms with obesity in Chinese north Han human subjects.Gene2012;494:237-41

[56] Hittel DS,Sarna N,Huffman KM.Myostatin decreases with aerobic exercise and associates with insulin resistance.Med Sci Sports Exerc2010;42:2023-9 PMCID:PMC2975387

[57] Saitoh M,Ebner N,Von Haehling S.Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy.JCSM Clinical Reports2017;2:1-10

[58] Garito T,Hompesch M.Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.Diabetes Obes Metab2018;20:94-102

[59] Rooks D,Praestgaard J,Laurent D.Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort.J Cachexia Sarcopenia Muscle2020;11:1525-34 PMCID:PMC7749589

[60] Witham MD,McMurdo ME.ACE inhibitors for sarcopenia--as good as exercise training?.Age Ageing2008;37:363-5

[61] Ata AM,Ekiz T.Reassessing sarcopenia in hypertension: STAR and ACE inhibitors excel.Int J Clin Pract2021;75:e13800

[62] Zhou LS,Wang XQ,Xiao Q.Effect of angiotensin-converting enzyme inhibitors on physical function in elderly subjects: a systematic review and meta-analysis.Drugs Aging2015;32:727-35

[63] Caulfield L,Walesby KE,Sayer AA.Effect of angiotensin system inhibitors on physical performance in older people - a systematic review and meta-analysis.J Am Med Dir Assoc2021;22:1215-21.e2 PMCID:PMC8189253

[64] Papadopoulou SK.Sarcopenia: a contemporary health problem among older adult populations.Nutrients2020;12:1293 PMCID:PMC7282252

[65] Hardee JP.Current pharmacotherapies for sarcopenia.Expert Opin Pharmacother2019;20:1645-57

[66] Seene T.Muscle weakness in the elderly: role of sarcopenia, dynapenia, and possibilities for rehabilitation.Eur Rev Aging Phys Act2012;9:109-17

[67] Nicklas BJ,Brinkley TJ.Exercise training and plasma C-reactive protein and interleukin-6 in elderly people.J Am Geriatr Soc2008;56:2045-52 PMCID:PMC2683336

[68] Starkie R,Jauffred S,Pedersen BK.Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans.FASEB J2003;17:884-6

[69] Lang T,Cawthon P,Taaffe DR.Sarcopenia: etiology, clinical consequences, intervention, and assessment.Osteoporos Int2010;21:543-59 PMCID:PMC2832869

[70] Phillips SM.Nutritional supplements in support of resistance exercise to counter age-related sarcopenia.Adv Nutr2015;6:452-60 PMCID:PMC4496741

[71] Tessier AJ.An update on protein, leucine, Omega-3 fatty acids, and vitamin D in the prevention and treatment of sarcopenia and functional decline.Nutrients2018;10:1099 PMCID:PMC6116139

[72] Coelho-Júnior HJ,Rodrigues B,Marzetti E.Relative protein intake and physical function in older adults: a systematic review and meta-analysis of observational studies.Nutrients2018;10:1330 PMCID:PMC6163569

[73] Kirk B,Amirabdollahian F.Exercise and dietary-protein as a countermeasure to skeletal muscle weakness: Liverpool Hope University - Sarcopenia Aging Trial (LHU-SAT).Front Physiol2019;10:445 PMCID:PMC6524700

[74] Kwak JY.Pharmacological interventions for treatment of sarcopenia: current status of drug development for sarcopenia.Ann Geriatr Med Res2019;23:98-104 PMCID:PMC7370765

[75] Rondanelli M,Peroni G.A systematic review on the effects of botanicals on skeletal muscle health in order to prevent sarcopenia.Evid Based Complement Alternat Med2016;2016:5970367 PMCID:PMC4804074

[76] Wei Y,Qiu Y.Prevention of muscle wasting by CRISPR/Cas9-mediated disruption of myostatin in vivo.Mol Ther2016;24:1889-91 PMCID:PMC5154488

[77] Fan J,Yang Y.MicroRNA-regulated proinflammatory cytokines in sarcopenia.Mediators Inflamm2016;2016:1438686 PMCID:PMC4921629

[78] Tompkins BA,Khan A.Allogeneic mesenchymal stem cells ameliorate aging frailty: a phase II randomized, double-blind, placebo-controlled clinical trial.J Gerontol A Biol Sci Med Sci2017;72:1513-22 PMCID:PMC5861900

[79] Zhu Y,Huang C,Jiang H.Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics.Theranostics2021;11:5675-85 PMCID:PMC8058725

[80] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[81] Powell EE,Rinella M.Non-alcoholic fatty liver disease.Lancet2021;397:2212-24

[82] Scapaticci S,Mohn A,Giannini C.Non-alcoholic fatty liver disease in obese youth with insulin resistance and type 2 diabetes.Front Endocrinol (Lausanne)2021;12:639548 PMCID:PMC8056131

[83] Eslam M,George J.International Consensus PanelMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.Gastroenterology2020;158:1999-2014.e1

[84] Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J Hepatol2016;64:1388-402

[85] Stefan N,Cusi K.Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.Lancet Diabetes Endocrinol2019;7:313-24

[86] Clark JM,Diehl AM.Nonalcoholic fatty liver disease.Gastroenterology2002;122:1649-57

[87] Pydyn N,Jura J.New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.Pharmacol Rep2020;72:1-12

[88] Pais R,Fedchuk L.LIDO Study GroupA systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.J Hepatol2013;59:550-6

[89] Angulo P,Dam-Larsen S.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology2015;149:389-97.e10 PMCID:PMC4516664

[90] Ekstedt M,Nasr P.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology2015;61:1547-54

[91] Kanwal F,Mapakshi S.Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.Gastroenterology2018;155:1828-37.e2 PMCID:PMC6279617

[92] Friedman SL,Rinella M.Mechanisms of NAFLD development and therapeutic strategies.Nat Med2018;24:908-22 PMCID:PMC6553468

[93] Sanyal AJ.Past, present and future perspectives in nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol2019;16:377-86

[94] Juanola O,Francés R.Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors.Int J Environ Res Public Health2021;18:5227 PMCID:PMC8155932

[95] Eslam M.Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology.Nat Rev Gastroenterol Hepatol2020;17:40-52

[96] Eslam M,Romeo S.Genetics and epigenetics of NAFLD and NASH: Clinical impact.J Hepatol2018;68:268-79

[97] Romeo S,Xing C.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.Nat Genet2008;40:1461-5 PMCID:PMC2597056

[98] Unalp-Arida A.Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population.Hepatology2020;71:820-34

[99] Ma J,Liu C.Improved diet quality associates with reduction in liver fat, particularly in individuals with high genetic risk scores for nonalcoholic fatty liver disease.Gastroenterology2018;155:107-17 PMCID:PMC6035111

[100] Sung KC,Lee JY,Wild SH.Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver.J Hepatol2016;65:791-7

[101] Vilar-Gomez E,Calzadilla-Bertot L.Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.Gastroenterology2015;149:367-78.e5; quiz e14-5

[102] Veena J,Sidgiddi S.Non-alcoholic fatty liver disease: need for a balanced nutritional source.Br J Nutr2014;112:1858-72

[103] DeFronzo RA,Schwenke DC.ACT NOW StudyPioglitazone for diabetes prevention in impaired glucose tolerance.N Engl J Med2011;364:1104-15

[104] Neuschwander-Tetri BA.Therapeutic landscape for NAFLD in 2020.Gastroenterology2020;158:1984-98.e3

[105] Gan D,Jia M.Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease.Clin Nutr2020;39:1124-30

[106] Hashimoto Y,Fukuda T,Yamazaki M.The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes.Endocr J2016;63:877-84

[107] Lee YH,Song K.Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).Hepatology2016;63:776-86

[108] Wijarnpreecha K,Raymond P,Ahmed A.Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA.Eur J Gastroenterol Hepatol2019;31:1121-8

[109] Montano-Loza AJ,Meza-Junco J.Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis.J Cachexia Sarcopenia Muscle2016;7:126-35 PMCID:PMC4864157

[110] Sherif O, Dhaliwal A, Newsome PN, Armstrong MJ. Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice.Expert Rev Gastroenterol Hepatol2020;14:197-205

[111] Okamura T,Hamaguchi M,Kojima T.The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: a population-based longitudinal study.Clin Res Hepatol Gastroenterol2020;44:375-83

[112] Mirza MS.Obesity, visceral fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease.ISRN Gastroenterol2011;2011:592404 PMCID:PMC3168494

[113] Petta S,Di Marco V.Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease.Aliment Pharmacol Ther2012;35:238-47

[114] Ismaiel A,Leucuta DC,Dumitrascu DL.The visceral adiposity index in non-alcoholic fatty liver disease and liver fibrosis-systematic review and meta-analysis.Biomedicines2021;9:1890 PMCID:PMC8698356

[115] Andrade LJ,Paraná R.Grading scale of visceral adipose tissue thickness and their relation to the nonalcoholic fatty liver disease.Arq Gastroenterol2014;51:118-22

[116] Francque S,Mertens I.Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension.Int J Obes (Lond)2011;35:270-8

[117] Lee S,Lee J.Visceral adiposity as a risk factor for lean non-alcoholic fatty liver disease in potential living liver donors.J Gastroenterol Hepatol2021;36:3212-8

[118] Xu C,Wang Y.Visceral adiposity index as a predictor of NAFLD: a prospective study with 4-year follow-up.Liver Int2018;38:2294-300

[119] Kure T,Imamura Y.Nonalcoholic fatty liver disease is associated with both subcutaneous and visceral adiposity: a cross-sectional study.Medicine (Baltimore)2019;98:e17879 PMCID:PMC6867727

[120] Vural Keskinler M,Sirin A.Visceral adiposity index as a practical tool in patients with biopsy-proven nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.Metab Syndr Relat Disord2021;19:26-31

[121] Nachit M,Thissen JP.Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.J Hepatol2021;75:292-301

[122] De Munck TJI,Lodewick T.Myosteatosis in nonalcoholic fatty liver disease: an exploratory study.Clin Res Hepatol Gastroenterol2021;45:101500

[123] Nachit M,Thissen JP.Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models.J Cachexia Sarcopenia Muscle2021;12:144-58 PMCID:PMC7890270

[124] Linge J,Dahlqvist Leinhard O.Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD.JHEP Rep2021;3:100197 PMCID:PMC7868647

[125] Nachit M,Rodriguez J.A dynamic association between myosteatosis and liver stiffness: results from a prospective interventional study in obese patients.JHEP Rep2021;3:100323 PMCID:PMC8321935

[126] Nachit M,Rodriguez J.An unsuspected link between myosteatosis and NAFLD grading in a prospective nutritional intervention study in obese patients.Hepatology2020;72:891A-2A

[127] Ebadi M.Clinical relevance of skeletal muscle abnormalities in patients with cirrhosis.Dig Liver Dis2019;51:1493-9

[128] Hsieh YC,Koo BK,Kim W.Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease.Liver Int2021;41:494-504

[129] Kim JA.Sarcopenia and fatty liver disease.Hepatol Int2019;13:674-87

[130] Jensen-Cody SO.Hepatokines and metabolism: deciphering communication from the liver.Mol Metab2021;44:101138 PMCID:PMC7788242

[131] Chadt A.Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease.Pflugers Arch2020;472:1273-98 PMCID:PMC7462924

[132] Postic C.Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.J Clin Invest2008;118:829-38 PMCID:PMC2254980

[133] Tilg H.Insulin resistance, inflammation, and non-alcoholic fatty liver disease.Trends Endocrinol Metab2008;19:371-9

[134] Brown MS.Selective versus total insulin resistance: a pathogenic paradox.Cell Metab2008;7:95-6

[135] Ipsen DH,Tveden-Nyborg P.Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.Cell Mol Life Sci2018;75:3313-27 PMCID:PMC6105174

[136] Peverill W,Skoien R.Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.Int J Mol Sci2014;15:8591-638 PMCID:PMC4057750

[137] Cusi K.Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis.Clin Liver Dis2009;13:545-63

[138] Sabio G,Mora A.A stress signaling pathway in adipose tissue regulates hepatic insulin resistance.Science2008;322:1539-43 PMCID:PMC2643026

[139] Coulon S,Colle I.Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease.Cytokine2012;59:442-9

[140] Lehrskov LL.The role of interleukin-6 in glucose homeostasis and lipid metabolism.Semin Immunopathol2019;41:491-9

[141] Sakurai Y,Yamauchi T.Role of insulin resistance in MAFLD.Int J Mol Sci2021;22:4156 PMCID:PMC8072900

[142] Zhang L,Samokhvalov V,Lopaschuk GD.Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle.Biochim Biophys Acta2010;1801:1-22

[143] Hegarty BD,Ye J,Kraegen EW.The role of intramuscular lipid in insulin resistance.Acta Physiol Scand2003;178:373-83

[144] Wu H.Skeletal muscle inflammation and insulin resistance in obesity.J Clin Invest2017;127:43-54 PMCID:PMC5199705

[145] Austin RL,Bouzakri K,Krook A.siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle.Diabetes2008;57:2066-73 PMCID:PMC2494681

[146] Aleffi S,Bertolani C.Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells.Hepatology2005;42:1339-48

[147] Angulo P,Petrovic LM,Lindor KD.Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease.J Hepatol2004;41:943-9

[148] Maeda N,Funahashi T.PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.Diabetes2001;50:2094-9

[149] Marra F.Adipokines in liver diseases.Hepatology2009;50:957-69

[150] Musso G,Biroli G.Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis.Am J Gastroenterol2005;100:2438-46

[151] Kellerer M,Metzinger E,Capp E.Leptin activates PI-3 kinase in C2C12 myotubes via janus kinase-2 (JAK-2) and insulin receptor substrate-2 (IRS-2) dependent pathways.Diabetologia1997;40:1358-62

[152] Minokoshi Y.Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle.Biochem Soc Trans2003;31:196-201

[153] Ceddia RB.Direct metabolic regulation in skeletal muscle and fat tissue by leptin: implications for glucose and fatty acids homeostasis.Int J Obes (Lond)2005;29:1175-83

[154] Wang F,Xiao J.Organ-organ communication: the liver’s perspective.Theranostics2021;11:3317-30 PMCID:PMC7847667

[155] Rittig K,Haupt A.High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population.Atherosclerosis2009;207:341-2

[156] Ix JH,Kanaya AM.Health ABC StudyFetuin-A and incident diabetes mellitus in older persons.JAMA2008;300:182-8 PMCID:PMC2779582

[157] Chattopadhyay M,Chatterjee SK.Impairment of energy sensors, SIRT1 and AMPK, in lipid induced inflamed adipocyte is regulated by Fetuin A.Cell Signal2018;42:67-76

[158] Hansen JS,Arous C.Circulating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio.J Clin Endocrinol Metab2016;101:550-60

[159] Brown ML,Ungerleider N.Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis.Obesity (Silver Spring)2011;19:1940-9 PMCID:PMC3179827

[160] Watt MJ,De Nardo W.The liver as an endocrine organ-linking NAFLD and insulin resistance.Endocr Rev2019;40:1367-93

[161] Jung TW,Kim HC,Jeong JH.Hyperlipidemia-induced hepassocin in the liver contributes to insulin resistance in skeletal muscle.Mol Cell Endocrinol2018;470:26-33

[162] Lan F,Chikamoto K.LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance.Diabetes2014;63:1649-64

[163] Misu H,Takayama H.A liver-derived secretory protein, selenoprotein P, causes insulin resistance.Cell Metab2010;12:483-95

[164] Succurro E,Marini MA.Low plasma insulin-like growth factor-1 levels are associated with reduced insulin sensitivity and increased insulin secretion in nondiabetic subjects.Nutr Metab Cardiovasc Dis2009;19:713-9

[165] Wyk JJ, Smith EP. Insulin-like growth factors and skeletal growth: possibilities for therapeutic interventions.J Clin Endocrinol Metab1999;84:4349-54

[166] Fernández AM,Yakar S.Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes.Genes Dev2001;15:1926-34 PMCID:PMC312754

[167] Laron Z,Klinger B.Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment.Metabolism1995;44:113-8

[168] Arturi F,Procopio C.Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I.J Clin Endocrinol Metab2011;96:E1640-4

[169] Møller N,Schmitz O,Jørgensen JO.Free fatty acids inhibit growth hormone/signal transducer and activator of transcription-5 signaling in human muscle: a potential feedback mechanism.J Clin Endocrinol Metab2009;94:2204-7

[170] Wilkes JJ,Gekakis N.Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance.Diabetes2009;58:1133-43 PMCID:PMC2671051

[171] García PS,Kambadur R,Csete M.Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting.Anesth Analg2010;111:707-9

[172] Nishikawa H,Ishii A.Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis.J Cachexia Sarcopenia Muscle2017;8:915-25 PMCID:PMC5700437

[173] Beaupere C,Fève B,Guillemain G.Molecular mechanisms of glucocorticoid-induced insulin resistance.Int J Mol Sci2021;22:623 PMCID:PMC7827500

[174] Jeong IK.The role of cortisol in the pathogenesis of the metabolic syndrome.Diabetes Metab J2012;36:207-10 PMCID:PMC3380124

[175] Roberge C,Langlois MF.Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity.Am J Physiol Endocrinol Metab2007;293:E1465-78

[176] Ferraù F.Metabolic comorbidities in Cushing’s syndrome.Eur J Endocrinol2015;173:M133-57

[177] Yasir M,Bansal P.Corticosteroid adverse effects. Treasure Island (FL): StatPearls Publishing; 2022.

[178] Yang M,Guan M.Role of steroid hormones in the pathogenesis of nonalcoholic fatty liver disease.Metabolites2021;11:320 PMCID:PMC8156407

[179] Lewis GF,Adeli K.Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes.Endocr Rev2002;23:201-29

[180] Birkenfeld AL.Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.Hepatology2014;59:713-23 PMCID:PMC3946772

[181] Woods C.The dehydrogenase hypothesis.Adv Exp Med Biol2015;872:353-80

[182] Morgan SA,Doig CL,Stewart PM.Glucocorticoids and 11β-HSD1 are major regulators of intramyocellular protein metabolism.J Endocrinol2016;229:277-86 PMCID:PMC5064767

[183] Morton NM,Fiévet C.Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice.J Biol Chem2001;276:41293-300

[184] Li H,Wang J.Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 attenuates high-fat diet-induced hepatic steatosis in mice.Drug Des Devel Ther2021;15:2309-24 PMCID:PMC8178584

[185] Li G,Crooke RM,Ginsberg HN.Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism.J Lipid Res2011;52:971-81 PMCID:PMC3073475

[186] Konopelska S,Hughes B.Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis.Clin Endocrinol (Oxf)2009;70:554-60

[187] Ahmed A,Brady T.A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease.PLoS One2012;7:e29531 PMCID:PMC3282715

[188] Candia R,Baudrand R.Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease.Liver Int2012;32:392-9

[189] Targher G,Rodella S,Zenari L.Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease.Clin Endocrinol (Oxf)2006;64:337-41

[190] Ragucci E,Lamerson M.Effects of mifepristone on nonalcoholic fatty liver disease in a patient with a cortisol-secreting adrenal adenoma.Case Rep Endocrinol2017;2017:6161348 PMCID:PMC5733994

[191] Rahimi L,Ismail-Beigi F.Glucocorticoid-induced fatty liver disease.Diabetes Metab Syndr Obes2020;13:1133-45 PMCID:PMC7171875

[192] Stefanaki C,Boschiero D.Chronic stress and body composition disorders: implications for health and disease.Hormones (Athens)2018;17:33-43

[193] Schakman O,Barbé C,Thissen JP.Glucocorticoid-induced skeletal muscle atrophy.Int J Biochem Cell Biol2013;45:2163-72

[194] Kuo T,Wang JC.Metabolic functions of glucocorticoid receptor in skeletal muscle.Mol Cell Endocrinol2013;380:79-88 PMCID:PMC4893778

[195] Schakman O,Thissen JP.Mechanisms of glucocorticoid-induced myopathy.J Endocrinol2008;197:1-10

[196] Amirouche A,Banzet S.Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle.Endocrinology2009;150:286-94

[197] McFarlane C,Thomas M.Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism.J Cell Physiol2006;209:501-14

[198] Choi JM,Kang SJ.Association between anxiety and depression and nonalcoholic fatty liver disease.Front Med (Lausanne)2020;7:585618 PMCID:PMC7848018

[199] Youssef NA,Binks M.Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease.Liver Int2013;33:1062-70

[200] Chen L,Qi H,Yu J.Correlation of sarcopenia and depressive mood in older community dwellers: a cross-sectional observational study in China.BMJ Open2020;10:e038089 PMCID:PMC7467510